Abstract
Overexpression of the antiapoptotic protein Mcl-1 provides a survival advantage to some cancer cells, making inhibition of this protein an attractive therapeutic target for the treatment of certain types of tumors. Herein, we report our efforts toward the identification of a novel series of macrocyclic Mcl-1 inhibitors featuring an α-hydroxy phenylacetic acid pharmacophore or bioisostere. This work led to the discovery of 1, a potent Mcl-1 inhibitor (IC50 = 19 nM in an OPM-2 cell viability assay) with good pharmacokinetic properties and excellent in vivo efficacy in an OPM-2 multiple myeloma xenograft model.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Administration, Oral
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Biological Availability
-
Cell Line, Tumor
-
Crystallography, X-Ray
-
Drug Design
-
Drug Stability
-
Female
-
Humans
-
Hydrogen Bonding
-
Mice, Nude
-
Multiple Myeloma / drug therapy
-
Myeloid Cell Leukemia Sequence 1 Protein / antagonists & inhibitors*
-
Myeloid Cell Leukemia Sequence 1 Protein / chemistry
-
Myeloid Cell Leukemia Sequence 1 Protein / metabolism
-
Phenylacetates / chemistry*
-
Rats, Sprague-Dawley
-
Structure-Activity Relationship
-
Sulfonamides / chemistry
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
MCL1 protein, human
-
Myeloid Cell Leukemia Sequence 1 Protein
-
Phenylacetates
-
Sulfonamides
-
2-hydroxyphenylacetic acid